Gas Vesicles and Acoustic Protein Nanostructures in Molecular Ultrasound Nanomedicine: Translational Archetypes, Biomaterial Design, and Barriers to Clinical Realization

Ultrasound is clinically established, portable, and repeatable, but its dominant contrast logic remains anatomical and perfusion-based. Gas vesicles (GVs), acoustic reporter genes (ARGs), targeted GV derivatives, and GV-containing release materials have introduced a protein-based route toward molecular ultrasound nanomedicine. Their translation, however, cannot be inferred from acoustic detectability alone. This Review examines GVs and related acoustic protein nanostructures as biomaterial and nanomedicine systems. We distinguish clinical microbubbles, purified GVs, exogenous GV-labeled cells, intracellular ARG systems, GV-based release materials, and prospective computationally designed acoustic protein nanostructures. These formats differ in biological setting, route of administration, pharmacologic burden, and evidentiary maturity. We define computational molecular sonography as a bounded organizing framework that links reporter design, acoustic signal representation, biological fate, exposure estimation, and clinician-governed safety. The strongest current evidence comes from natural and engineered GV systems, including pressure-dependent collapse, nonlinear detection, gas vesicle protein C (GvpC)-mediated surface engineering, blood-component interactions, and reporter-gene imaging. By contrast, fully de novo acoustic protein nanostructures remain prospective rather than in vivo-ready. The major translational barriers include shell mechanics and stability, surface corona and immune clearance, repeat-dose safety, toxicology, manufacturing consistency, critical quality attributes, and Sim-to-Real uncertainty in tissue and acoustic fields. Future clinical value will require standardized biomaterial characterization, direct acoustic phenotyping, reporter-sensitive acquisition, and regulatory-grade control of product and exposure. Ultrasound visibility is therefore necessary but insufficient; translation will depend on aligning material design, biological fate, signal interpretation, and safety as a coupled problem. Plain Language Summary: Ultrasound is widely used in healthcare because it can show the body in real time without ionizing radiation. Most ultrasound examinations show anatomy, blood flow, or tissue movement. They usually do not show molecular events at a disease site. This review discusses a newer group of ultrasound-related tools called acoustic protein nanostructures. These include gas vesicles, which are tiny gas-filled protein structures made by microorganisms, and acoustic reporter genes, which can make selected cells produce ultrasound-detectable signals. The review explains why these technologies should not be treated as one single class. Clinical microbubbles, purified gas vesicles, reporter genes, cell-labeling methods, and gas-vesicle-based drug-release materials are used in different ways and face different safety and manufacturing problems. The main conclusion is cautious. Gas vesicles can produce useful ultrasound signals in preclinical studies, but being visible by ultrasound is not enough for clinical use. Future work must show reproducible production, stable acoustic behavior, safe biological clearance, acceptable repeat dosing, and clear clinician oversight before these systems can become clinical nanomedicine tools.